Clinical characteristics and mortality predictors of patients with cancer hospitalized by COVID-19 in a pediatric third-level referral center

Laura-Monserrat Hernández-Regino; Manuel De Jesús Castillejos-López; Arnoldo Aquino-Gálvez; Liliana Velasco-Hidalgo; Alda García-Guzmán; Marco Aguilar-Ortiz; Rocío Cárdenas-Cardos; Luz María Torres-Espíndola

doi:10.3389/fped.2022.960334

Clinical characteristics and mortality predictors of patients with cancer hospitalized by COVID-19 in a pediatric third-level referral center

Front Pediatr. 2022 Jul 28:10:960334. doi: 10.3389/fped.2022.960334. eCollection 2022.

Authors

Laura-Monserrat Hernández-Regino¹, Manuel De Jesús Castillejos-López², Arnoldo Aquino-Gálvez³, Liliana Velasco-Hidalgo⁴, Alda García-Guzmán⁴, Marco Aguilar-Ortiz⁴, Rocío Cárdenas-Cardos⁴, Luz María Torres-Espíndola¹

Affiliations

¹ Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, Mexico.
² Department of Hospital Epidemiology and Infectology, National Institute of Respiratory Diseases "Ismael Cosío Villegas," Mexico City, Mexico.
³ Laboratory of Molecular Biology, Pulmonary Fibrosis Department, National Institute of Respiratory Diseases "Ismael Cosío Villegas," Mexico City, Mexico.
⁴ Oncology Service, National Institute of Pediatrics, Mexico City, Mexico.

Abstract

Background: More than 135 million COVID-19 cases (coronavirus disease 2019) have been reported worldwide until today, with over 2.9 million deaths. Several studies have demonstrated that disease severity is lower in the pediatric population than in adults; however, differences are described in patients with chronic diseases, including oncological patients. Current world literature suggests patients with comorbidities, including cancer, have an increased risk of unfortunate outcomes. Therefore, our objective was to describe the clinical characteristics and epidemiological factors associated with mortality in a cohort of pediatric cancer patients hospitalized for COVID-19.

Methods: This is a retrospective, descriptive study of the cases of patients with cancer hospitalized for COVID-19. A total of 40 pediatrics were included in the analysis. Data from pediatric patients with COVID-19 included clinical and epidemiological records, laboratory, imaging studies, COVID-19 diagnostic methods, and medical treatment.

Results: Of the 40 pediatric patients admitted with cancer with a confirmed diagnosis of COVID-19, 42.5% were solid tumors, 40% leukemias, and 17.5% lymphomas. The clinical parameters associated with mortality were stage IV tumor (p = 0.029) and intubation (p < 0.001). The biochemical factors associated with lower survival were thrombocytopenia under 25,000 cells/mm³ (p < 0.001), D-dimer over 1 μg/ml (p = 0.003), clinical malnutrition (p = 0.023), and disseminated intravascular coagulation (p = 0.03).

Conclusion: Our findings showed that the fever was the most frequent symptom, and the clinical parameters associated with mortality were stage IV tumor, intubation, saturation percentage, RDW, platelets, creatinine, ALT, D-dimer, ferritin, and FiO2 percentage. The thrombocytopenia, D-dimer, nutritional status, and disseminated intravascular coagulation were significantly associated with lower survival.

Keywords: COVID-19; cancer; mortality; pediatrics; predictor.